ATC Code M01AC05
Formula C13H10ClN3O4S2
Molar Mass (g·mol−1) 371,82
Physical State solid
Melting Point (°C) 225–230
PKS Value 4,78
CAS Number 70374-39-9
PUB Number 54690031
Drugbank ID DB06725
Solubility sparingly soluble in water


Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic (pain-relieving), anti-inflammatory and antipyretic (fever-reducing) properties. It is available in oral and parenteral formulations. Lornoxicam is used to treat various types of pain, especially inflammatory conditions of the joints, osteoarthritis, surgery, sciatica, and other inflammatory conditions.



Like other NSAIDS, the anti-inflammatory and analgesic effects of lornoxicam are due to its inhibitory action on prostaglandin and thromboxane synthesis by inhibiting both COX-1 and COX-2. This results in the reduction of inflammation, pain, fever and swelling mediated by prostaglandins.


Lornoxicam is rapidly and almost completely absorbed from the GI tract (90-100%). It is 99% bound to plasma proteins (almost exclusively to serum albumin). Lornoxicam is completely metabolized by CYP2C9, so only negligible amounts of intact lornoxicam are excreted unchanged in the urine. Approximately 2/3 of the drug is excreted by the liver and 1/3 by the kidneys in the active form. The half-life is 3-5 hours.

Drug Interactions

Drug interactions are typical with NSAIDs. Combination with vitamin K antagonists such as warfarin increases the risk of bleeding. Combination with ciclosporin may result in decreased renal function and, in rare cases, acute kidney injury. Lornoxicam may also increase the adverse effects of lithium, methotrexate and digoxin and its derivatives. The effect of diuretics, ACE inhibitors and angiotensin II receptor antagonists may be reduced, but this is only relevant in patients with special risks such as heart failure.


Side effects

Lornoxicam has side effects similar to other NSAIDs, mostly mild such as gastrointestinal discomfort (nausea and diarrhea) and headache.

Severe but rare side effects include bleeding, bronchospasm, and the extremely rare Stevens-Johnson syndrome.

Toxicological Data

LD50 (rat, oral): 3.857 mol-kg-1


  • PubChem
  • Drugbank
  • Aktories, Förstermann, Hofmann, Starke: Allgemeine und spezielle Pharmakologie und Toxikologie, Elsvier, 2017
Markus Falkenstätter

Markus Falkenstätter

Markus Falkenstätter ist Autor zu pharmazeutischen Themen in der Medizin-Redaktion von Medikamio. Er befindet sich im letzten Semester seines Pharmaziestudiums an der Universität Wien und liebt das wissenschaftliche Arbeiten im Bereich der Naturwissenschaften.

Mag. pharm Stefanie Lehenauer

Mag. pharm Stefanie Lehenauer

Stefanie Lehenauer ist seit 2020 freie Autorin bei Medikamio und studierte Pharmazie an der Universität Wien. Sie arbeitet als Apothekerin in Wien und ihre Leidenschaft sind pflanzliche Arzneimittel und deren Wirkung.

Your personal medicine assistent

afgis-Qualitätslogo mit Ablauf Jahr/Monat: Mit einem Klick auf das Logo öffnet sich ein neues Bildschirmfenster mit Informationen über Medikamio GmbH & Co KG und sein/ihr Internet-Angebot: medikamio.com/ This website is certified by Health On the Net Foundation. Click to verify.

Search our database for drugs, sorted from A-Z with their effects and ingredients.


All substances with their common uses, chemical components and medical products which contain them.


Causes, symptoms and treatment for the most common diseases and injuries.

The contents shown do not replace the original package insert of the medicinal product, especially with regard to dosage and effect of the individual products. We cannot assume any liability for the correctness of the data, as the data was partly converted automatically. A doctor should always be consulted for diagnoses and other health questions. Further information on this topic can be found here.